MoonLake Immunotherapeutics (MLTX): Total Assets
$424.43M
As of 2025-12-31
$573.95M
As of 2026-06-30
+76.8%
3-year compound annual growth
+29.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $424.43M | -11.2% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $477.93M | -9.2% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $526.54M | +585.2% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $76.84M | +693.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $9.68M | -91.7% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $116.63M | n/a | 2022-02-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $424.43M | -11.2% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $418.43M | +54.1% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $430.99M | -15.5% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $432.97M | +24.1% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $433.81M | +718.5% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $408.89M | +49.2% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $404.21M | -19.4% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $448.38M | +172.9% |
Compare MLTX, STOK, BCAX, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗